Table C-70. Physical and chemical characteristics of all currently marketed Gadolinium agents for MRI

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Generic Name** | **Trade Name** | **Company** | **Acronym** | **Year Approved** | **Charge** | **Type** | **Dose (mml/kg)** | **Concentration (M)** |
| Gadobenate dimeglumine | MultiHance® | Bracco Diagnostics, Princeton, NJ, USA | Gd-BOPTA | 2004 | Di-ionic | Liver-specific | 0.1 | 0.5 |
| Gadobutrol | Gadavist | Bayer HealthCare Pharmaceutical Inc., Wayne, NJ, USA | Gd-BT-DO3A | 2011 | Nonionic | ECF | 0.1 | 1.0 |
| Gadopentetate dimeglumine | Magnevist | Bayer HealthCare Pharmaceutical Inc., Wayne, NJ, USA | Gd-DTPA | 1988 | Di-ionic | ECF | 0.1 | 0.5 |
| Gadodiamide | Omniscan | GE Healthcare, Princeton, NJ, USA | Gd-DTPA-BMA | 1993 | Nonionic | ECF | 0.1 | 0.5 |
| Gadoversetamide | Optimark | Mallinckrodt, St. Louis, MO, USA | Gd-DTPA-BMEA | 1999 | Nonionic | ECF | 0.1 | 0.5 |
| Gadoxetic acid disodium salt | Eovist® | Bayer HealthCare, Wayne, NJ, USA | Gd-EOB-DTPA | 2008 | Di-ionic | Liver-specific | 0.025 | 0.25 |
| Gadoteridol | ProHance | Bracco Diagnostics, Princeton, NJ, USA | Gd-HP-DO3A | 1992 | Nonionic | ECF | 0.1 | 0.5 |
| Gadofosveset trisodium | Ablavar® | Lantheus Medical Imaging, North Billerica, MA, USA | MS325 | 2008 | Tri-ionic | Blood-pool | 0.03 | 0.25 |

ECF: Extracellular fluid.

Taken from Chang et al.178and Yang et al.230